ATS View
한국어

Genematrix KRX:109820KOSDAQ

진매트릭스 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days8
DART filings, 7 days1
Articles tracked22since Sep 11

In Q2 2026, Genematrix reported revenue of ₩2.9bn, up 8.1% year on year, and operating profit of ₩393m. Genematrix (진매트릭스) appeared in 8 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 27 with 8 articles. The most common catalyst was clinical & approvals (6). It was most often mentioned alongside GFC Life Science.

Filing signals Turnaround Clinical trial filing Screener

Genematrix quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩2.9bn+8.1%₩393m
margin 13.5%		₩689m
Q1 2026₩2.5bn+0.9%−₩327m
margin −13.0%		−₩221m
Q4 2025 derived₩2.9bn+9.2%−₩191m
margin −6.7%		−₩923m
Q3 2025₩2.6bn-1.7%−₩109m
margin −4.2%		₩266m
Q2 2025₩2.7bn-8.9%−₩91m
margin −3.4%		−₩391m
Q1 2025₩2.5bn+38.2%−₩288m
margin −11.5%		−₩786m
Q4 2024 derived₩2.6bn-8.1%−₩435m
margin −16.6%		−₩350m
Q3 2024₩2.6bn+7.1%−₩148m
margin −5.6%		−₩193m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Genematrix top stories 2 weeks, by number of outlets

  1. 1
    진매트릭스, 'A형간염 백신 임상' 서울대와 계약
    3 outlets · 3 articlesFirst report Oct 27 11:22 뉴시스경제
  2. 2
    진매트릭스 ‘국산 A형간염 백신’ 임상 1상 착수
    2 outlets · 3 articlesFirst report Oct 27 13:13 이데일리Clinical trial
  3. 3
    [BIO톡]케이바이오솔루션, FDA 510(k) 허가 연속 달성 外 지에프씨생명과학·진매트릭스
    1 outlets · 1 articlesFirst report Oct 27 15:31 글로벌경제신문Regulatory approvalGFC Life Science
  4. 4
    진매트릭스, ‘GMAI-02’ 1상 계약…A형간염 백신 국산화
    1 outlets · 1 articlesFirst report Oct 27 12:05 바이오타임즈

Latest Genematrix news Korean headlines